Cagri and GLP-1S act on entirely different receptor systems. Cagri is a long-acting amylin analog, while GLP-1S is a GLP-1 receptor agonist. The two are frequently studied together because their mechanisms are complementary.
| Property | Cagri | GLP-1S |
|---|---|---|
| Category | Long-acting amylin analog (dual amylin/calcitonin receptor agonist) | GLP-1 receptor agonist |
| Mechanism of Action | Activates amylin and calcitonin receptors; used to study amylin receptor signaling and receptor activity-modifying protein (RAMP) complexes | Activates the GLP-1 receptor; raises intracellular cAMP in receptor-expressing cell lines |
| Molecular Weight | ~4,409 Da (lipidated amylin analog) | ~4,113 Da |
| Research Focus | Amylin/calcitonin receptor signaling, combination assays with GLP-1 receptor agonists | GLP-1 receptor-selective signaling assays |
| Receptor Target | Amylin receptors (AMY1-3) + calcitonin receptor | GLP-1 receptor (selective) |
| Half-Life | ~7-8 days (lipidation enables albumin binding) | ~7 days (C-18 fatty diacid, albumin binding) |
Cagri and GLP-1S target two independent receptor systems: the amylin/calcitonin receptor family and the GLP-1 receptor. Both are lipidated peptides with roughly week-long half-lives. Rather than direct competitors, they are best understood as complementary tools; combination research (Cagri-Sema) explores how simultaneous engagement of the two receptor systems behaves in cell-based assays.
Cagri is a long-acting amylin analog that signals through amylin and calcitonin receptors, while GLP-1S is a GLP-1 receptor agonist. Both have ~7-day half-lives. They engage independent receptor systems, and combination research (Cagri-Sema) studies how the two behave together in assay models.
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.